- US Capitol Capsule: When drugs may cause cancer: A knotty challenge for FDA
- Surviving a Scandal: How to Expect the Unexpected
- Industry scrambles to defuse row over "satanic" campaign against South African IP plans
- 4Q preview: Amgen, Biogen, BMS, Celgene, Novartis, Pfizer and Roche
- Interview: building on Spiriva – Boehringer Ingelheim's Allan Hillgrove
- INTERVIEW: Dr Reddy's CEO on the 'windshield and rear view mirror'